Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations

Cancer Research

Volumn 65, Issue 21, 2005, Pages 10096-10103

  Judkins, Thaddeus ^a   Hendrickson, Brant C ^a   Deffenbaugh, Amie M ^a   Eliason, Kristilyn ^a   Leclair, Benoît ^a   Norton, Michael J ^a   Ward, Brian E ^a   Pruss, Dmitri ^a   Scholl, Thomas ^a  

^a Myriad Genetic Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN;

ALLELE; ARTICLE; BREAST CANCER; DNA SEQUENCE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HUMAN; LETHALITY; MAJOR CLINICAL STUDY; MISSENSE MUTATION; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TRANSGENIC MOUSE;

ALLELES; BREAST NEOPLASMS; GENES, BRCA1; HAPLOTYPES; HUMANS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 27544483543     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1241     Document Type: Article

References (32)

1. Coughlin SS, Khoury MJ, Steinberg KK. BRCA1 and BRCA2 gene mutations and risk of breast cancer. Public health perspectives. Am J Prev Med 1999;16:91-8.
2. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000;356:1876-81.
3. Eng C, Brody LC, Wagner TM, et al. Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet 2001;38:824-33.
4. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665-76.
5. Judkins T, Hendrickson BC, Deffenbaugh AM, Scholl T. Single nucleotide polymorphisms in clinical genetic testing: the characterization of the clinical significance of genetic variants and their application in clinical research for BRCA1. Mutat Res 2005;573:168-79.
6. Frank TS, Manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998;16:2417-25.
7. Hakem R, de la Pompa JL, Sirard C, et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 1996;85:1009-23.
8. Hakem R, de la Pompa JL, Elia A, Potter J, Mak TW. Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nat Genet 1997;16:298-302.
9. Boyd M, Harris F, McFarlane R, Davidson HR, Black DM. A human BRCA1 gene knockout. Nature 1995;375: 541-2.
10. Kuschel B, Gayther SA, Easton DF, Ponder BA, Pharoah PD. Apparent human BRCA1 knockout caused by mispriming during polymerase chain reaction: implications for genetic testing. Genes Chromosomes Cancer 2001;31:96-8.
11. Abkevich V, Zharkikh A, Deffenbaugh AM, et al. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 2004;41:492-507.
12. Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997;278:1242-50.
13. Judkins T, Schwensen C, Hendrickson BC, Harpending HC, Barrus J, Scholl T. Automated haplotyping in BRCA1 and localization of polymorphisms on alleles. Am J Hum Genet 2003;73:409.
14. Liu X, Barker DF. Evidence for effective suppression of recombination in the chromosome 17q21 segment spanning RNU2-BRCA1. Am J Hum Genet 1999;64:1427-39.
15. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
16. Osorio A, de la Hoya M, Rodriguez-Lopez R, et al. Over-representation of two specific haplotypes among chromosomes harbouring BRCA1 mutations. Eur J Hum Genet 2003;11:489-92.
17. Hendrickson BC, Pruss D, Lyon E, Scholl T. Application of haplotype pair analysis for the identification of hemizygous loci. J Med Genet 2003;40:346-7.
18. Tancredi M, Sensi E, Cipollini G, et al. Haplotype analysis of BRCA1 gene reveals a new gene rearrangement: characterization of a 19.9 KBP deletion. Eur J Hum Genet 2004;12:775-7.
19. Vallon-Christersson J, Cayanan C, Haraldsson K, et al. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 2001;10:353-60.
20. Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997;17:79-83.
21. Bar-Sade RB, Kruglikova A, Modan B, et al. The 185de1AG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. Hum Mol Genet 1998;7:801-5.
22. Shen JC, Rideout WM III, Jones PA. High frequency mutagenesis by a DNA methyltransferase. Cell 1992; 71:1073-80.
23. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
24. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481-7.
25. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297:606-9.
26. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-7.
27. Oddoux C, Struewing JP, Clayton CM, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996;14:188-90.
28. Offit K, Levran O, Mullaney B, et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 2003;95:1548-51.
29. Thompson D, Easton DF, Goldgar DE. A hill-likelihood method for the evaluation of causality of sequence variants from family data. Am J Hum Genet 2003;73:652-5.
30. Monteiro AN, Humphrey JS. Yeast-based assays for detection and characterization of mutations in BRCA1. Breast Dis 1998;10:61-70.
31. Phelan CM, Dapic V, Tice B, et al. Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet 2005;42:138-46.
32. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 2004;75:535-44.